Cell Therapy Developer SBioMedics Raises 2 Billion Won in Paid-in Capital Increase... "For Operating Fund Procurement"
Esbiomedics, a KOSDAQ-listed cell therapy developer, announced on the 13th that it has decided to raise 2 billion KRW through a third-party allotment paid-in capital increase to secure operating funds and other expenses.
A total of 271,320 new common shares will be issued at a price of 25,800 KRW per share. The third-party allotment recipients include SYS Holdings (116,280 shares) and Dongkook Pharmaceutical (58,140 shares), among others.
Hot Picks Today
Samsung Quietly Prepared for 10 Years, Finally Reaches the Top... Surpasses US Giant to Become 'World No. 1'
- "It's Not Time to Sell Yet, KOSPI Headed for 9,000"...The Signal the Securities Industry Is Watching [Weekend Money]
- "If You Bring a Family Member's ID Number, I'll Give You More"... Doctor Illegally Administered Propofol 4,700 Times
- "Bought on Company Faith, Got 400% Return" Executive’s Account Swells to 15.9 Billion Won with 13 Billion Won Profit
- "How Similar Were They?... 'Used Cousin's ID and Passed'—Bizarre Incident at Early Voting Station"
The company stated that the purpose of the third-party allotment capital increase is "to achieve management objectives through operating funds and other funds (clinical trial costs)."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
